Heat preconditioning ameliorates hepatocyte viability after cold preservation and rewarming, and modulates its immunoactivity

Dopamine impairs functional integrity of rat hepatocytes through nuclear factor kappa B activity modulation: An in vivo, ex vivo, and in vitro study

Dopamine (DA) is commonly used to maintain the hemodynamic stability of brain-dead donors despite its controversial effects on organ functions. This study aimed at examining the hemodynamic effect of DA in a rat brain-dead model in vivo, alteration of hepatocyte integrity in liver grafts after ex vivo preservation, and changes in cultured clone-9 hepatocytes including cellular viability, cell cycle, apoptotic regulators, and lipopolysaccharide (LPS)-stimulated nuclear factor kappa B (NF-κB) signaling machinery. Although in vivo findings demonstrated enhanced portal venous blood flow and hepatic microcirculatory perfusion after DA infusion, no apparent advantage was noted in preserving hepatocyte integrity ex vivo. In vitro, prolonged exposure to high-dose DA reduced proliferation and induced G1 growth arrest of clone-9 hepatocytes with concomitant decreases in B cell lymphoma 2 (BCL2)/B cell lymphoma 2-associated X protein (BAX) and heat shock protein 70/BAX protein ratios and intracellular NF-κB p65. Moreover, DA pretreatment suppressed LPS-elicited inhibitor of κBα phosphorylation and subsequent NF-κB nuclear translocation, suggesting that DA may down-regulate NF-κB signaling, thereby reducing expression of antiapoptotic regulators, such as BCL2. In conclusion, despite augmentation of hepatic perfusion, DA infusion failed to preserve hepatocyte integrity both in vivo and ex vivo. In vitro findings demonstrated that high-dose DA may hamper the function of NF-κB signaling machinery and eventually undermine functional integrity of hepatocytes in liver grafts.

Hypothermic storage of hepatocytes used for bioartificial liver support system: current status and recent advances

The problem that high-quality hepatocytes are difficult to obtain restricts the use of bioartificial liver support system (BLASS) in clinical practice. Finding an effective way to preserve hepatocytes and constructing a "ready-to-use" hepatocyte bank would efficiently promote the development of the BLASS. Nowadays, the methods for hypothermic storage of hepatocytes could be classified into two types: conventional hypothermic storage at 4 °C or subzero nonfreezing storage, and cryopreservation at -80 °C or -196 °C. Each type of hypothermic storage method has its advantages and disadvantages. Many factors may affect the effect of hypothermic storage (cryopreservation), such as storage solution and cryoprotective agent. Although the precise mechanism underlying the death of hepatocytes during hypothermic storage is not well understood, numerous studies have indicated that apoptosis plays an important role in hypothermic storage injury.

High concentration of magnolol induces hepatotoxicity under serum-reduced conditions

Although magnolol is cytoprotective against warm ischemia/reperfusion injury, its effect on cold preservation has not been fully investigated. This study aimed at examining whether magnolol maintains the liver graft integrity after cold preservation and elucidating the underlying mechanisms in terms of apoptotic signaling under both normothermic and hypothermic conditions. After being preserved in Ringer's lactate (RL) at 4 degrees C for 6h ex vivo, the magnolol-treated grafts demonstrated significantly higher AST, ALT, and LDH levels in perfusates than those from negative controls. TUNEL staining showed no difference in the number of apoptotic nuclei in both groups, whereas a more intense apoptotic signal in magnolol-treated grafts was shown as compared with the controls. In vitro data showed no significant difference in viability of RL-preserved clone-9 hepatocytes between the magnolol-treated and control groups, while magnolol pretreatment at 30min before cold preservation prominently induced hepatocyte cell death. RT-PCR and Western blotting analyses revealed a suppression in Bcl-2, but an up-regulation in Bax expression in clone-9 cells after magnolol treatment. Magnolol suppressed the ratios of NF-kappaB to I-kappaBalpha protein contents and I-kappaBalpha phosphorylation induced by TNF-alpha, and potentiated mitochondrial cytochrome c release and subsequent caspase-3 cleavage. Conversely, caspase-3 inhibitor attenuated magnolol-induced hepatotoxicity. We concluded that magnolol could not protect liver grafts from cold ischemia/reperfusion injury. High concentration of magnolol under serum-reduced conditions attenuates NF-kappaB-mediated signaling and induces intrinsic apoptotic pathway, thereby inducing in vitro hepatotoxicity.

Subzero nonfreezing storage of C3A hepatocytes for use in bioartificial liver support systems

AIM: To investigate whether subzero nonfreezing storage (-0.8 °C) is superior to conventional cold storage in preservation of C3A hepatocytes for use in bioartificial liver support systems.

METHODS: C3A hepatocytes suspended in University of Wisconsin (UW) solution were divided into three groups: subzero nonfreezing group (-0.8 °C), zero nonfreezing group (0 °C) and control group (4 °C). After 24, 48 and 72 hours of hypothermic storage, cell viability and apoptosis were detected by flow cytometry; intracellular adenosine triphosphate (ATP) content, lactate dehydrogenase (LDH) release, lactic acid production, urea synthesis and albumin secretion were determined; and cell morphological changes were observed.

RESULTS: Compared to the zero nonfreezing group and the control group, after 72 hours of hypothermic storage, the percentage of viable C3A hepatocytes was significantly higher (86.49% ± 2.80% vs 81.50% ± 2.83% and 77.83% ± 3.40%, respectively; both P < 0.05), and cell apoptosis rate was significantly lower (1.26% ± 0.84% vs 5.34% ± 1.20% and 9.16% ± 1.99%, respectively; both P < 0.05) in the subzero nonfreezing group. Lactic acid and LDH production was more significantly suppressed (lactic acid: 10.38 μg/10⁶ cells ± 1.40 μg/10⁶ cells vs 12.02 μg/10⁶ cells ± 1.64 μg/106 cells and 17.41 μg/10⁶ cells ± 2.40 μg/10⁶ cells; LDH: 80.10 U/L ± 11.10 U/L vs 120.04 U/L ± 14.32 U/L and 148.98 U/L ± 15.37 U/L, respectively; all P < 0.05), and the ability of hepatocytes to synthesize urea and secrete albumin was better maintained in the subzero nonfreezing group (both P < 0.05). Moreover, cells in the subzero nonfreezing storage group had lower death rate and better cellular morphology. A burr-like structure around the cell membrane and an intracellular vacuole-like structure were found in cells in the zero nonfreezing group and the control group, but not in the subzero nonfreezing group.

CONCLUSION: Subzero nonfreezing storage (-0.8 °C) of hepatocytes to construct a "ready-to-use" hepatocyte bank like the "blood bank" will efficiently promote the development of bioartificial liver support systems.